Imagion Biosystems (ASX:IBX) has updated investors on its planned Phase 2 HER2 breast cancer clinical trial to be conducted in the US.

Regenerative medicine company Orthocell (ASX:OCC) has recorded its first sales revenue from its Remplir nerve repair product in the US.

AusBiotech has welcomed 27 new member organisations in the first half of 2025, reinforcing the sector’s growth and momentum.

PYC Therapeutics (ASX:PYC) has announced it is progressing the two-part trial of its PYC-003 for Polycystic Kidney Disease.

AusBiotech has announced the 2025 appointments to its state committees, which the organisation describes as a key mechanism for hearing from and engaging with the breadth and diversity of its membership nationwide.

Neurotech International (ASX: NTI) has announced the publication of its Phase 1/2 clinical trial results for Rett syndrome in the peer-reviewed scientific journal, Journal of Paediatrics and Child Health.

Syntara (ASX:SNT) has announced that the World Health Organization has formally granted the International Non-Proprietary Name of amsulostat to its advanced clinical development asset SNT-5505.

Clinical stage biotechnology company Neurizon Therapeutics (ASX:NUZ) has executed an exclusive global license agreement with Elanco Animal Health.

AusBiotech, the national voice of Australia’s life sciences industry, is seeking a head of investment to lead the next chapter in its sector leadership.

AusBiotech is now inviting member submissions for the upcoming October 2025 edition of the Australasian Biotechnology journal — the sector’s long-standing platform for sharing insights, innovation, and expertise across the life sciences ecosystem.

Amplia Therapeutics (ASX:ATX) has announced that an additional confirmed partial response has been recorded in its ongoing ACCENT clinical trial in pancreatic cancer.

Australian antiviral drug development company Island Pharmaceuticals (ASX:ILA) has announced the appointment of Jason Carroll as its non-executive chairman.

Prescient Therapeutics (ASX:PTX) has opened its share purchase plan to raise $7 million to advance PTX-100 through Phase 2 clinical development toward potential regulatory approval.

Tetratherix (ASX:TTX) has officially listed on the Australian Securities Exchange after raising $25 million in its initial public offering.

Percheron Therapeutics (ASX:PER) has entered into a worldwide exclusive license agreement with Hummingbird Bioscience, a venture-backed biotechnology company based in Singapore, for HMBD-002, a monoclonal antibody therapy with potential applications in various cancer indications.

Australian company Atmo Biosciences has received US FDA 510(k) clearance for its gas capsule system, meaning it can be marketed and sold in the country.

LTR Pharma (ASX:LTP) has announced that it has achieved its latest regulatory milestone for SPONTAN with the successful completion of extractables testing and the launch of its leachables studies.